This story is from June 30, 2015

DRL recalls two generic drugs in US

City-headquartered pharma giant Dr Reddy's Laboratories (DRL) has announced that it is voluntarily recalling two generic drugs, manufactured at its Bachupally facility, from the US market.
DRL recalls two generic drugs in US
HYDERABAD: City-headquartered pharma giant Dr Reddy's Laboratories (DRL) has announced that it is voluntarily recalling two generic drugs, manufactured at its Bachupally facility, from the US market.
According to the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories is recalling `Divalproex Sodium' extended-release tablets used for the treatment of seizures and anti-hypertension tablets ` Amlodipine Besylate Atorvastatin Calcium'.
So far, the company has recalled 7,479 units (100 count) and 2,544 units (500 count) of Divalproex Sodium extendedrelease tablets from the US market as it has failed dissolution specifications and crossed the expiry time. The drug, which is used to treat certain types of seizures, is being recalled under the `class-II' classification.
Further, DRL has also initiated recall of Amlodipine Besylate and Atorvastatin Calcium tablets, which is used in the treatment of high blood pressure and chest pain. The recall of these hypertension tablets is being made under “class III“ classification “We have initiated a voluntary recall of Divalproex. This has been done as an abundant precautionary measure by the company , based on observations related to the products' dissolution specifications. The observations are being investigated at our end and we are confident of a satisfactory resolution at the earliest. Pending submission of the investigation report to the USFDA, we would not like to comment further at this stage,“ DRL vice-president and head of corporate communications Calvin Printer said.
End of Article
FOLLOW US ON SOCIAL MEDIA